Zydus Lifesciences has informed that it enclosed a copy of press release dated May 17, 2024 titled ‘Zydus and MSN announces exclusive licensing and supply agreement for Cabozantinib Tablets (generic version of CABOMETYX®) for the US market’.
The above information is a part of company’s filings submitted to BSE.